(3aR,4R,6aS)-4-(5-oxohexyl)-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: (3aR,4R,6aS)-4-(5-oxohexyl)-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one
• 化学式: C₁₁H₁₈N₂O₂S
• 分子量: 242.34
• InChiKey: YPKZJRGKHXINPU-OPRDCNLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE
  申请人：Ipsen Pharma S.A.S.

  公开号：US20160206700A1

  公开（公告）日：2016-07-21

  The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.

  本发明提供了一种改善炎症、抑制促炎细胞因子和/或趋化因子表达以及治疗与炎症发作相关的各种疾病和/或病况的方法，通过给予选择性的天然hGhrelin类似物来治疗需要治疗此类病况的受试者。
• SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES
  申请人：Waldmann Herbert

  公开号：US20120316192A1

  公开（公告）日：2012-12-13

  The present invention relates to novel substituted indolo[2,3-a]quinolizines and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo[2,3-a]quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo[2,3-a]quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo[2,3-a]quinolizines is disclosed in the present invention.

  本发明涉及新型的取代吲哚[2,3-a]喹诺里嗪及其立体异构体和/或这些化合物的药用可接受盐，以及包含至少一种这些取代吲哚[2,3-a]喹诺里嗪的药物组合物，以及药用可接受的载体、辅料和/或稀释剂。所述新型取代吲哚[2,3-a]喹诺里嗪已被确认为通过诱导强烈的有丝分裂延迟、染色体错位和有丝分裂三极和/或多极化导致细胞周期停止和凋亡，用于癌症的预防和治疗的有用物质。此外，本发明还公开了取代吲哚[2,3-a]喹诺里嗪的合成方法。
• TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
  申请人：BAHADOOR Adilah

  公开号：US20110274655A1

  公开（公告）日：2011-11-10

  Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables R A , R B and R C are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

  本文提供了式(I)的四唑酮FASN抑制剂或其药用可接受形式；其中变量RA、RB和RC在此处定义。本文还提供了所述化合物的药物组合物以及它们用于治疗各种疾病的方法，如过度增殖性疾病、炎症性疾病、与肥胖有关的疾病和微生物感染。
• NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND
  申请人：Fukase Koichi

  公开号：US20100008857A1

  公开（公告）日：2010-01-14

  A label with which labeling is easy when labeling a molecule, i.e., a label that has a high reaction rate upon labeling and that produces a high reaction yield, as well as a precursor for the production of the label are provided. This is achieved by a hexatriene-β-carbonyl compound represented by Formula (I), a hexatriene-β-carbonyl compound represented by Formula (II), a hexatriene-β-carbonyl compound represented by Formula (III) and a hexatriene-β-carbonyl compound represented by Formula (IV). (wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 and Z are as defined in the specification)
• AFFINITY TAG LABELED NUCLEOSIDES AND USES
  申请人：Complete Genomics, Inc.

  公开号：US20170240961A1

  公开（公告）日：2017-08-24

  Nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.